| Identification | Back Directory | [Name]
1,2-Cyclopentanediol, 3-[7-aMino-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyriMidin-3-yl]-5-(2-hydroxyethoxy)-, (1S,2S,3R,5S)- | [CAS]
1251765-07-7 | [Synonyms]
T437700
Ticagrelor-8
Ticagrelor DP3
Ticagrelor Impurity 78
Ticagrelor metabolite M5
Ticagrelor EP Impurity A
Ticagrelor Impurity 8(DP3)
Ticagrelor Metabolite-M5 D7
Ticagrelor Impurity H (UL134)
Ticagrelor Related Compound 45
Ticagrelor Related Compound 45 (DP3)
Ticagrelor Impurity 8(Ticagrelor BP Impurity A)
Ticagrelor impurity B: amino deprotected impurity
Ticagrelor metabolite M-5,Ticagrelor metabolite M5
(1S,2S,3R,5S)-3-(7-amino-5-propylsulfanyltriazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
(1S,2S,3R,5S)-3-(7-amino-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
1,2-Cyclopentanediol, 3-[7-aMino-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyriMidin-3-yl]-5-(2-hydroxyethoxy)-, (1S,2S,3R,5S)-
Ticagrelor impurity 7/Ticagrelor TFR Amino Impurity/(1S,2S,3R,5S)-3-[7-Amino-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-1,2-cyclopentanediol
Ticagrelor Metabolite-M5Q: What is
Ticagrelor Metabolite-M5 Q: What is the CAS Number of
Ticagrelor Metabolite-M5 Q: What are the applications of
Ticagrelor Metabolite-M5 | [Molecular Formula]
C14H22N6O4S | [MDL Number]
MFCD31694232 | [MOL File]
1251765-07-7.mol | [Molecular Weight]
370.427 |
| Chemical Properties | Back Directory | [Boiling point ]
711.4±70.0 °C(Predicted) | [density ]
1.75±0.1 g/cm3(Predicted) | [solubility ]
DMSO (Slightly), Methanol (Slightly, Heated) | [form ]
Solid | [pka]
13.26±0.70(Predicted) | [color ]
White to Off-White | [Stability:]
Hygroscopic | [CAS DataBase Reference]
1251765-07-7 |
| Hazard Information | Back Directory | [Uses]
AR-C133913XX is an metabolte of Ticagrelor (T437700) which is the first reversible oral P2Y12 receptor antagonist, provides faster, greater, and more consistent ADP-receptor inhibition than Clopidogrel. Ticagrelor is used in the treatment of acute coronary syndromes (ACS). |
|
|